02616 CSTONE PHARMA-B
- 1.120
- +0.240+27.27%
CSTONE PHARMA-B News
Cornerstone Pharmaceuticals (2616.HK): Performance meets expectations CS5001 completes multiple dose exploration
Cornerstone Pharmaceuticals (2616.HK): Lowering 2023-24E profit forecast and target price
Morgan Stanley: Maintains Cornerstone Pharmaceuticals (02616) “Buy” rating with target price of HK$7
Cornerstone Pharmaceutical (2616.HK): The performance is in line with expectations, and the development path is clear
Southwest Securities: First offer to Cornerstone Pharmaceutical-B (02616) with a “buy” rating target price of HK$7.56
Cornerstone Pharmaceutical (2616.HK): Performance inflection point, new engine development path clear
Cornerstone Pharmaceutical (2616.HK): The company issued a positive profit forecast for FY22; positive business progress is expected in FY23
Cornerstone Pharmaceutical (2616.HK): Differentiation Strategy Leads to Harvest Period
Cornerstone Pharmaceutical-B (02616.HK): Sales of precision therapeutics in the first half of the year exceeded market expectations, cost reductions and efficiency increased significantly
Cornerstone Pharmaceutical (2616.HK): There is still uncertainty in the short term, and the huge global potential of early product pipelines has yet to be realized
Cornerstone Pharmaceutical (2616.HK): Further transformation into a biopharmaceutical company in 2022
Cornerstone Pharmaceutical (2616.HK): The prospects for evonib to be approved domestically are good; R&D capabilities have been further verified
Cornerstone Pharmaceutical (02616.HK): The product harvest period has arrived, pipeline 2.0 continues to advance
Cornerstone Pharmaceutical (02616.HK): Growth value further realized
Cornerstone Pharmaceutical (2616.HK): Achieved a number of milestones in the first half of 2020
Cornerstone Pharmaceutical (02616.HK): Stock price performance lags behind and still has potential to make up for gains
Cornerstone Pharmaceutical-B (02616.HK) In-depth Research Report: R&D and introduction of dual-core drivers, Cornerstone Pharmaceutical is on the rise
Cornerstone Pharmaceutical (2616.HK): A promising franchise company in the field of anti-tumor drugs
Cornerstone Pharmaceutical (2616.HK): Clinical R&D Drives Emerging Oncology Immunotherapy
Cornerstone Pharmaceutical-B (02616.HK): IPO Information
Analysis
Price Target
No Data
